Peptides Medicine Grade Raw Material Powder Polypeptides API GLP-1 Semaglutide CAS 910463-68-2

         As a new type of long-acting GLP-1 analogue, semaglutide has the advantages of reducing the number of administrations and being relatively economical compared with previous similar drugs. The drug can reduce the risk of hypoglycemic events, delay gastric emptying and central appetite suppression, and can control body weight while stably lowering blood sugar.
         Semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, and its effect in the treatment of type 2 diabetes is better.
         Semeglutide is a novel GLP-1 analogue administered subcutaneously once a week. Semaglutide is a long-acting GLP-1 analogue developed by Novo Nordisk for 1/w subcutaneous injection. Compared with liraglutide, semaglutide has a longer fatty chain and increased hydrophobicity, but semaglutide is modified by short-chain PEG, and its hydrophilicity is greatly enhanced. After PEG modification, it can not only bind tightly with albumin Chemicalbook, cover the DPP-4 enzyme hydrolysis site, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation. Novo Nordisk's semaglutide beats DPP-4's sitagliptin, and the originator of GLP-1 long-acting exenatide (it should be designed to compare head-to-head with lilly's trulicity, bullying has long been on the market). In the test, high-dose Soma decreased A1C by 1.6%, and reduced body weight by up to 6kg.
          Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217) is a long-acting glucagon-like peptide 1 (GLP-1) analog, an agonist of the GLP-1 receptor, with potential type 2 diabetes (T2DM) therapeutic efficacy.
          Semaglutide regulates blood sugar through various mechanisms such as increasing glucose-dependent insulin secretion, reducing glucagon secretion, delaying early gastric emptying, and reducing food intake. benefit.